Clinical Trial Update: Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of copanlisib and nivolumab in patients with recurrent or refractory diffuse large B-cell lymphoma or primary mediast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-01-23